Recap Of Friday's Biotech Catalysts - End Of the Day Summary
- The U.S. Food and Drug Administration (FDA) has approved Axsome Therapeutics’ (NASDAQ: AXSM) lead asset AUVELITY (dextromethorphan HBr -bupropion HCl) extended-release tablets for the treatment of major depressive disorder (MDD) in adults. Axsome shares traded in a range of $50.5 to $61.11 on a day volume of 21.95 million shares, closed regular trading session at $59.55.
- The Swiss Agency for Therapeutic Products (Swissmedic) has approved Cara Therapeutics’ (NASDAQ: CARA) lead candidate KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult hemodialysis patients. Cara shares traded in a range of $10.88 to $11.29 on a day volume of 266.29 thousand shares, closed regular trading session at $11.26.
- Verona Pharma plc (NASDAQ: VRNA) announces its development partner, Nuance Pharma, has received clearance from the Center of Drug Evaluation (CD") for its Investigational New Drug (IND) application to conduct both Phase 1 and Phase 3 studies with ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in mainland China. Verona shares traded in a range of $11.95 to $12.84 on a day volume of 409.89 thousand shares, closed regular trading session at $12. The company shares are currently trading at $11.65, down 2.92 percent in the after-hours trading session.
- Moleculin Biotech (NASDAQ: MBRX) announced preliminary results from the third cohort of the first-in-human Phase 1a study of WP1122, consisted of 10 subjects dosed with 32 mg/kg or placebo in the dose escalation trial evaluating the safety and pharmacokinetics (PK) of WP1122 in healthy volunteers in the United Kingdom (UK). Moleculin shares traded in a range of $1.68 to $1.77 on a day volume of 33.61 thousand shares, closed regular trading session at $1.68.
- Sorrento Therapeutics (NASDAQ: SRNE) announced the IND clearance by the China National Medical Products Administration (NMPA) for a Phase I study of its oral main viral protease inhibitor, STI-1558, in subjects with COVID-19 in a MAD study in China. Sorrento shares traded in a range of $1.84 to $2.01 on a day volume of 11.35 million shares, closed regular trading session at $1.86.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Biotech Catalysts - EOD SummaryBiotech News Penny Stocks Health Care Small Cap FDA General
